NASDAQ:DARA

(DARA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range
$0.32
$0.33
52-Week Range N/A
Volume13,850 shs
Average Volume118,843 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive DARA News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.


(DARA) logo

About (DARA)

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











(DARA) (NASDAQ:DARA) Frequently Asked Questions

What stocks does MarketBeat like better than (DARA)?

Wall Street analysts have given (DARA) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but (DARA) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were (DARA)'s earnings last quarter?

(DARA) (NASDAQ:DARA) issued its quarterly earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company had revenue of $1.18 million for the quarter, compared to analyst estimates of $0.83 million.
View (DARA)'s earnings history
.

What other stocks do shareholders of (DARA) own?

What is (DARA)'s stock symbol?

(DARA) trades on the NASDAQ under the ticker symbol "DARA."

What is (DARA)'s official website?

The official website for (DARA) is www.darabiosciences.com.

Where are (DARA)'s headquarters?

(DARA) is headquartered at 8601 Six Forks Rd Ste 160, RALEIGH, NC 27615-2965, United States.

How can I contact (DARA)?

(DARA)'s mailing address is 8601 Six Forks Rd Ste 160, RALEIGH, NC 27615-2965, United States. The specialty pharmaceutical company can be reached via phone at +1-816-9147027.


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.